JWA
ACAD icon

JFS Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

JFS Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25K Buy
89
+20
+29% +$440 ﹤0.01% 1568
2026
Q1 		$1.54K Sell
69
-3
-4% -$72 ﹤0.01% 1582
2025
Q4 		$1.92K Buy
72
+35
+95% +$836 ﹤0.01% 1557
2025
Q3 		$790 Buy
37
+7
+23% +$166 ﹤0.01% 1671
2025
Q2 		$648 Buy
+30
New +$558 ﹤0.01% 1650

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JFS Wealth Advisors's ACAD Position: Q2 2026 in Review

JFS Wealth Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 29% in Q2 2026, buying an estimated $440 and bringing the position to 89 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

JFS Wealth Advisors first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • JFS Wealth Advisors held 89 shares of Acadia Pharmaceuticals worth $2.25K as of Q2 2026.
  • JFS Wealth Advisors bought 20 Acadia Pharmaceuticals shares in Q2 2026, an estimated $440.
  • Acadia Pharmaceuticals made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1568 holding.
  • JFS Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.